|
|
Volumn 24, Issue 9, 2016, Pages 1503-1504
|
|
A cure for hemophilia: The promise becomes a reality
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BLOOD CLOTTING FACTOR 8;
COMPLEMENTARY DNA;
PARVOVIRUS VECTOR;
ADENO ASSOCIATED VIRUS VECTOR;
BLOOD CLOTTING FACTOR 9;
NEUTRALIZING ANTIBODY;
SINGLE STRANDED DNA;
BIOTECHNOLOGY;
CD8+ T LYMPHOCYTE;
CLINICAL TRIAL (TOPIC);
CODON;
COST EFFECTIVENESS ANALYSIS;
DISEASE SEVERITY;
EDITORIAL;
GENE SEQUENCE;
GENETIC TRANSDUCTION;
HEALTH CARE COST;
HEMOPHILIA;
HUMAN;
LIVER CELL;
NONHUMAN;
TOXIC HEPATITIS;
VIRAL GENE THERAPY;
GENETICS;
HEMOPHILIA A;
HEMOPHILIA B;
MOLECULARLY TARGETED THERAPY;
TRENDS;
CLINICAL OUTCOME;
CLINICAL RESEARCH;
IMMUNOLOGICAL TOLERANCE;
LIVER TOXICITY;
VIRAL GENE DELIVERY SYSTEM;
VIRUS GENOME;
HEMOPHILIA A;
HEMOPHILIA B;
HUMANS;
MOLECULAR TARGETED THERAPY;
|
|
EID: 84990857883
PISSN: 15250016
EISSN: 15250024
Source Type: Journal
DOI: 10.1038/mt.2016.169 Document Type: Editorial |
|
Times cited : (14)
|
|
References (1)
|
